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Abstract
Background: In Brazil, the rate of cervical cancer remains high despite the availability of screening programs. With
ongoing vaccine development and implementation, information on the prevalence of specific HPV types is needed,
particularly among high-risk populations, such as HIV-infected women.
Methods: We performed a study of HIV-infected women in Rio de Janeiro, Brazil, who underwent cervical HPV
genotype testing between 2005-2013. We examined the prevalence of high-risk HPV types and the patterns of
high-risk HPV type clustering. Using logarithmic binomial regression, we estimated the risk of abnormal cytology by
HPV genotype result.
Results: Of the 562 women included, 498 (89 %) had at least one HPV type detected. 364 women (65 %) had at
least one high-risk HPV type detected and 181 (32 %) had more than one high-risk type detected. HPV 58 was the
most frequent HPV type detected overall (prevalence 19.8 % [95 % confidence interval 16.4–23.1]), followed by HPV
53 (prevalence 15.5 % [12.5–18.5]) and HPV 16 (prevalence 13 % [10.2–15.8]). Women infected with more than one
high-risk HPV type were younger, had lower CD4+ lymphocyte counts, and were more likely to be infected with
HPV 16 or 18. In adjusted analyses, presence of more than one high-risk HPV type was associated with a two-fold
increased risk of abnormal cytology after adjusting for presence of individual high-risk type, age, and CD4+ lymphocyte
count (adjusted prevalence ratios 1.88–2.07, all p <0.001). No single high-risk HPV type was statistically associated with
abnormal cytology after adjusting for the presence of more than one high-risk HPV type.
Conclusions: In the largest study of cervical HPV genotypes among HIV-infected women in Latin America, infection by
high-risk HPV types other than 16 or 18 and infection by more than one high-risk HPV types were common. Infection
by more than one high-risk type was more strongly associated with abnormal cervical cytology than any individual
high-risk HPV type, highlighting the need for multi-valent HPV vaccines.
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Background
Latin America has one of the highest incidence and
mortality rates of cervical cancer in the world [1]. As in
other regions, in Latin America, high-risk human papil-
lomavirus (HPV) type 16 has been strongly associated
with risk of high-grade cervical dysplasia and cervical
cancer [2]. In Brazil, high-risk HPV types have been ob-
served to be highly prevalent in women with both nor-
mal and abnormal cervical cytology [3, 4].
For women with HIV infection, the risks and conse-
quences of HPV infection are even greater. Women with
HIV infection have higher prevalence of high-risk HPV
types, are more likely to be infected with more than one
HPV type, and are at increased risk of cervical dysplasia
and cervical cancer [5–11]. HIV-infected women are
more likely to have abnormal cervical cytology and dys-
plasia associated with high-risk HPV types other than 16
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or 18 [12–14]. Among HIV-infected women in Latin
America, prevalence of cervical HPV infection in women
with normal cervical cytology has been estimated at
57 %, similar to the prevalence observed in HIV-infected
women in Africa (57 %) and higher than that observed
in HIV-infected women in Asia (31 %), Europe (32 %),
or North America (31 %) [13]. A recent large study of
pregnant HIV-infected women in Rio de Janeiro, Brazil,
noted an overall cervical HPV prevalence of 84 %, 80 %
of whom were infected by high-risk types [15]. While
some studies have shown a protective effect, combin-
ation antiretroviral therapy (cART) has not consistently
been observed to affect rates of cervical intraepithelial
neoplasia and only modestly improves HPV infection
clearance [7, 16–21].
Given their increased risk, HIV-infected women are
recommended to receive frequent screening for cervical
dysplasia [22]. Vaccines targeting common high-risk
HPV types are effective in reducing risk of cervical dys-
plasia and are immunogenic in HIV-infected women [23,
24]. However, these vaccines are not yet widely available
in many places in the world, particularly in low- and
middle-income countries [1, 25]. As next-generation
HPV vaccines are developed, knowledge of high-risk
HPV epidemiology, particularly among high-risk groups
such as HIV-infected women, is of critical importance.
To address this need, we performed a prevalence study
of cervical HPV infection among a cohort of HIV-
infected women in Rio de Janeiro, Brazil. In this study,
we describe the prevalence of HPV types, patterns of
clustering, and patient clinical and demographic factors
associated with high-risk HPV cervical infection and ab-
normal cytological outcomes.
Methods
To examine the epidemiology of type-specific HPV in-
fections, we performed an analysis of all HIV-infected
women followed at the Women’s Cohort of the Instituto
Nacional de Infectologia Evandro Chagas (INI), Fundção
Oswaldo Cruz, who underwent HPV genotype testing by
line assay at cohort entry. This study was approved by
institutional ethics review boards of INI and Vanderbilt
University.
The Women’s HIV Cohort at INI is an observational
study of the natural history of HIV infection in women
that began in 1996. After recruitment from the general
HIV clinic and signing informed consent, women complete
surveys on sexual and gynecologic history and undergo
routine cytology-based cervical cancer screening by Papa-
nicolaou (Pap) tests and hybrid capture detection of onco-
genic HPV DNA (types 16, 18, 31, 33, 35, 45, 51, 52, 58,
and 68). Women with abnormal cytological results are re-
ferred for colposcopy and biopsies, as indicated according
to the Brazilian Ministry of Health Guidelines. HIV history
and pertinent laboratory results are obtained from the HIV
clinical database [26].
This study included women who enrolled in the
Women’s HIV Cohort between 2005 and 2013. From
2005 through 2013, all women entering the cohort
underwent cervical linear-array testing for HPV geno-
types along with routine Pap smear testing at cohort
entry. Cervical samples were collected using a cervical
brush or swab and stored in conservative media (STM,
Qiagen, Valencia, CA, USA). DNA was extracted by
phenol-chloroform standard method. Five μL aliquots were
used for HPV detection and genotyping using the Linear-
Array HPV Genotyping Test (Roche Molecular Systems
Inc., Alameda, CA, USA) which targets low-risk HPV types
(6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67, 69, 70, 71,
72, 73, 81, 82, 83, 84, IS39, and CP6180) and high-risk
(oncogenic) HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, and 68). Women with inadequate specimens or
failed genotype testing were excluded from the study. HPV
type designation of low-risk or high-risk (oncogenic) was
performed in accordance to internationally-recognized
classification [27]. Cervical cytology analysis was per-
formed at the INI Pathology Laboratory using standard-
ized methods and the Bethesda rating system: atypical
squamous cells unknown significance (ASC-US), atypical
glandular cells (AGC), low-grade squamous intraepithelial
lesion (LSIL), atypical squamous cells – cannot exclude
high-grade lesion (ASC-H), high-grade squamous intrae-
pithelial lesion (HSIL), or cancer. For analyses, AG-US
and ASC-H results were included with ASC-US.
We first described the distribution of low- and high-risk
HPV types observed among all women. For descriptive
purposes, overall prevalence rates and 95 % confidence in-
tervals based upon normal distributions were calculated
for the most frequently occurring types. We next exam-
ined the prevalence of each high-risk HPV type and of
more than one high-risk type by cervical cytology out-
come (normal, ASC-US, LSIL, and HSIL or cancer), de-
fined as the proportion of women with the cytological
outcome who were positive for the high-risk HPV type.
To examine patterns of clustering of high-risk HPV types,
we graphically examined the relative frequencies of each
high-risk HPV pairing observed in women with abnormal
cytology.
We compared patient characteristics at the time of
HPV testing associated with HPV genotype subsets:
women uninfected with HPV, women infected with only
low-risk HPV types, women infected with one high-risk
HPV type, and women infected with more than one
high-risk HPV type. Demographic and social factors in-
cluded age, race, education, living situation, income, and
tobacco use. We also examined sexual and health behav-
ior, as well as HIV clinical variables including CD4+
lymphocyte nadir (defined as lowest recorded CD4+
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lymphocyte prior to and up to 90 days after the HPV
testing date), current CD4+ lymphocyte count (closest
recorded value within one year), current HIV RNA value
(up to one year prior), and total months since initiation of
combination antiretroviral therapy (cART). Comparisons
of HPV genotype group were performed using Wilcoxon
rank sum and Fisher exact tests for continuous and cat-
egorical variables, respectively.
To study the association of each high-risk HPV type
and presence of more than one high-risk type with ab-
normal cytology outcomes, we calculated prevalence
ratios using logarithmic binomial regression. Prevalence
ratios for abnormal cytology (defined as cytology re-
sults of ASC-US or higher) by demographic (age, race,
education), social (tobacco use, presence of HIV-
infected sexual partner), and clinical (CD4+ lymphocyte
nadir and count, HIV RNA, and cART history) factors
were first examined using unadjusted analyses (data not
shown). Unadjusted prevalence ratios of each high-risk
HPV type and presence of more than one high-risk
HPV type for abnormal cytology were calculated. To
develop the most parsimonious model possible, demo-
graphic and clinical variables highly statistically signifi-
cantly associated with abnormal cytology (p <0.01)
were retained in adjusted models. Final models for each
high-risk HPV type included the individual high-risk
HPV type, age, CD4+ lymphocyte count, and presence
of more than one high-risk HPV. In adjusted analyses,
the detection of more than one high-risk HPV type re-
flects the relative risk of abnormal cytology associated
with multiple high-risk HPV types, after accounting
for the detection of the individual high-risk type in-
cluded in the model, age, and CD4+ lymphocyte count.
The individual high-risk type included in the model in
the adjusted model reflects the risk of abnormal cy-
tology adjusting for background risk associated with
co-infections, age, and CD4+ lymphocyte count. To
avoid co-linearity, for each model, presence of more
than one high-risk type does not by definition include
only those co-infections involving individual high-risk
HPV of the model. P values were adjusted for multiple
comparisons by Bonferroni correction in the final ad-
justed models (statistically significant threshold of p <
0.004).
Along with HPV types 26, 66, 67, 70, 73, and 82, HPV
53 has been noted to be possibly oncogenic and may not
truly represent low-risk infection [28, 29]. As HPV 53
was found to be highly prevalent in our cohort, we ex-
amined its prevalence, clustering, and association with
abnormal cytology using the same methods as described
for the high-risk HPV types.
Statistical analyses and figures were performed using
Stata 12.1 (Stata Corporation, College Station, Texas,
USA). All p values were two-sided.
Results
From 2005 to 2013, 590 women enrolled in the women’s
cohort and underwent HPV linear array genotyping at
the time of cervical cancer screening. HPV genotype re-
sults for 28 women (4.7 %) failed or were incomplete,
resulting in 562 women who were included in our study.
Women with failed genotype testing who were excluded
were statistically similar to those included with respect
to age, race, education, and sexual history (data not
shown). Excluded women had similar CD4+ lymphocyte
counts at cohort entry compared to women included in
the analyses (median 437 vs. 436 cells/mL respectively,
p = 0.67). Excluded women had a higher proportion of
failed hybrid capture tests (25 vs. 1 %, p < 0.001); how-
ever, among women with hybrid capture results, ex-
cluded and included women had similar rates of positive
hybrid capture results (57 vs. 44 % respectively, p =
0.27). Lastly, excluded and included women had similar
proportions of abnormal cervical cytology outcomes (19
vs. 30 % respectively, p = 0.38).
The frequencies of each HPV type observed in the co-
hort are shown in Fig. 1. Overall, the most frequent
HPV type observed was high-risk type 58 (prevalence:
19.8 %, 95 % confidence interval [CI]: 16.4–23.1). After
HPV 58, HPV 16 was the second most frequently ob-
served high-risk HPV detected (prevalence: 13 %, 95 %
CI: 10.2–15.8). HPV 18 was detected in 10.3 % of
women (95 % CI: 7.8–12.8). Infection by more than one
high-risk HPV type was observed in 32.2 % of women
(95 % CI: 28.3–36.1).
Table 1 describes the demographic, social, and clinical
characteristics of women included in analyses according
to HPV genotype result. Overall, 364 women (65 %) had
at least one high risk HPV type detected and nearly half
of those women had more than one high risk type
present (n = 181). Women with infection by more than
one high-risk type were younger than women with only
one high-risk HPV type detected and were more likely
to report a known HIV-infected sexual partner. They did
not differ in reported condom use, tobacco, or hormonal
contraception use. Women with more than one high-
risk type had lower CD4+ lymphocyte count nadirs com-
pared to women with no HPV types detected but did
not differ from women with only one high-risk HPV
type detected. However, women with more than one
high-risk type had lower CD4+ lymphocyte counts at
the time of HPV testing compared to both HPV negative
women and those with only one high-risk type detected.
Women with more than one high-risk type had a greater
number of low-risk HPV types detected and were more
often infected with HPV 16 or 18. Women with any
high-risk type more frequently had abnormal cytology,
with presence of more than one high-risk type associated
with even higher frequency of abnormal cytology.
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The prevalence of high-risk HPV types and presence
of more than one high-risk type by cytology result are
shown in Fig. 2. Overall, HPV 58 was the most common
high-risk HPV type detected in women with normal cy-
tology, ASC-US, LSIL, and HSIL or cervical cancer.
HPV 16 was detected in 22 % (95 % CI: 13–31 %) of
women with LSIL and 24 % (95 % CI: 10–46 %) of
women with HSIL or cancer. HPV 18 was detected in
13 % (95 % CI: 6–20 %) and 18 % (95 % CI: 0–38 %) of
women with LSIL and HSIL or cancer, respectively.
Prevalence of infection by more than one high-risk type
increased from 24 % (95 % CI: 20–29 %) among women
with normal cytology to 65 % (95 % CI: 36–89 %) among
women with HSIL or cancer.
We next examined the pairing frequencies of high-risk
HPV types observed in women with abnormal cytology
results (n = 166). Figure 3 displays each high-risk HPV
pair observed whereby the size of the circle at the inter-
section of each high risk HPV type corresponds to the
relative frequency of the observed pairing. The circles
representing the intersection of each high-risk type and
“none” reflect the relative frequencies of each high-risk
type occurring in monoinfection. Among women with
abnormal cytology, HPV 58 was the most common
high-risk type detected in monoinfection and in multiple
infections. However, the frequencies of individual high-
risk pairings were relatively low and distributed across
all high-risk HPV types. The pairing combinations of HPV
58 and 31 (n = 10, prevalence = 6 %), 58 and 56 (n = 9,
prevalence = 5 %), and 16 and 56 (n = 8, prevalence = 5 %)
were the most frequently observed high-risk HPV pairs.
HPV 16 paired most often with HPV 58 (n = 7) and 68
(n = 7). Some high-risk HPV types occurred more fre-
quently in paired infections than monoinfection, in-
cluding HPV 39 and 68.
Results from unadjusted and adjusted logarithmic bi-
nomial regression models for abnormal cytology are re-
ported in Table 2. In unadjusted analyses, a number of
individual high-risk HPV types were statistically associ-
ated with abnormal cytology, including HPV 16, 31, 33,
35, 39, 52, and 68. In addition, age (prevalence ratio [PR]
per 5 year increase 0.92 [95 % CI: 0.86–0.98]), CD4+
lymphocyte count (PR per 100 cells/ml increase 0.90
[95 % CI: 0.85–0.95]), and presence of more than one
high risk HPV type (PR 2.16 [95 % CI: 1.68–2.76]) were
statistically associated with abnormal cytology results
in unadjusted analyses. Notably, tobacco use, number
of lifetime sexual partners, condom use, HIV RNA, and
cART history were not statistically associated with ab-
normal cytology in unadjusted analyses (data not
shown). In adjusted models adjusting for multiple com-
parisons, the prevalence ratio point estimates for each
high-risk HPV type were attenuated and no longer sta-
tistically significant, based upon a Bonferroni corrected
p value of <0.004 for significance. However, in every ad-
justed model, presence of more than one HPV type
remained strongly associated with an approximate 2-
fold increased risk of abnormal cervical cytology, re-
gardless of the individual high-risk HPV type assessed
in each model.
Fig. 1 Prevalence of all HPV types. Includes HPV genotype data on all 562 women
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The second most frequently observed type was HPV
53 (prevalence: 15.5 %, 95 % CI: 12.5–18.5 %) and ana-
lyses examined its epidemiology given its weakly car-
cinogenic risk. Of the 87 women infected with HPV 53,
67 (77 %) were also infected with a high-risk HPV type.
Thirty-two (19 %) of all women with HPV 53 infection
had abnormal cytology; however, 31 of these women
were also infected with high-risk HPV types. One
woman with HPV 53 infection without co-infection by a
high-risk type was found to have ASC-US on cytology.
In unadjusted analyses, infection by HPV 53 was associ-
ated with increased risk of abnormal cytology (PR = 1.3,
95 % CI: 0.96–1.78). In a model adjusted for age, CD4
lymphocyte count, and co-infection with high-risk types,
the association was no longer observed (aPR = 0.90, 95 %
CI 0.67–1.21).
Discussion
In this large study of HIV-infected women, we found
that infection with high-risk HPV types and infection
Table 1 Demographic, social, and clinical characteristics of women by HPV genotype result







N (%) 64 (11.4) 134 (23.8) 183 (32.6) 181 (32.2) 562
Age in years, median (IQR) 37.4 (30.3–41.3) 38.5 (31.1–45.5) 36.0 (29.9–44.0) 32.7 (26.5–41.3)a 35.8 (29.3–43.6)
Non-white race, n (%) 50 (79.4) 99 (73.9) 129 (71.3) 124 (68.9) 402 (72.0)
Years of formal education, median (IQR) 8 (5–11) 8 (5–11) 8 (5–11) 9 (6–11)b 8 (5–11)
Monthly income (US$), median (IQR) 400 (255–600) 425 (250–750) 400 (232.5–750) 450 (232.5–800) 415 (235–750)
Married/living with partner, n (%) 34 (53.1) 85 (63.4) 100 (54.6) 102 (56.4) 321 (57.1)
Age at sexual debut, median (IQR) 16 (14–18) 16 (15–18) 16 (15–18) 16 (15–18) 16 (15–18)
Number of lifetime sexual partners, median (IQR) 5 (4–12) 5 (3–8) 5 (3–10) 5 (3–9) 5 (3–10)
Condom use with last sexual intercourse, n (%) 37 (57.8) 86 (65.7) 117 (65.4) 118 (66.3) 358 (64.9)
HIV-infected current sexual partner, n (%) 9 (14.1) 38 (28.4)c 28 (15.3) 50 (27.6)c, d 125 (22.2)
Number of pregnancies, median (IQR) 2 (1–4) 3 (2–4) 3 (1–4) 2 (1–3)a 2 (1–4)
Current hormonal contraceptive use, n (%) 16 (25.0) 19 (14.3) 27 (14.8) 33 (18.2) 95 (17.0)
Current tobacco usee, n (%) 10 (15.6) 37 (20.6) 36 (20.2) 31 (23.1) 114 (20.5)
Nadir CD4+ lymphocyte countf, median (IQR) 302 (190–570) 307 (155–500) 255 (128–483) 256 (90–414)b 274 (128–467)
CD4+ lymphocyte count at HPV testg, median (IQR) 528 (326–827) 512 (309–679) 433 (309–631) 398 (251–549)a, b 436 (296–679)
HIV RNA <400 copies/mlh, n (%) 27 (42.2) 63 (47.0) 74 (40.4) 62 (34.3) 226 (40.2)
Total months since cART initiation at HPV test, median (IQR) 1.65 (0–12.5) 2.5 (0–15.1) 3.6 (0–16.9) 2.0 (0–13.5) 2.5 (0–14.13)
Total number of low-risk HPV types detected, median (IQR) 0 1 (1–2) 1 (1–2) 2 (1–3)a 1 (0–2)
HPV 16 or 18 detected, n (%) 0 0 42 (23.0) 82 (45.3)d 122 (22.1)
Cytology results, n (%)
Any Abnormal 7 (10.9) 22 (16.4) 53 (24.0)c 84 (46.4)c, d 166 (29.5)
ASC-US or AGC 5 (7.8) 14 (10.5) 19 (10.4) 26 (14.4) 64 (11.4)
LSIL 1 (1.6) 7 (5.2) 30 (16.4)c 47 (26.0)c, d 85 (15.1)
HSIL 1 (1.6) 1 (0.8) 4 (2.2) 10 (5.5) 16 (2.9)
Cancer 0 0 0 1 (0.6) 1 (0.2)
aRank sum test of comparison with one HR HPV group p < 0.05
bRank sum test of comparison with no HPV group p < 0.05
cFisher exact test of comparison with no HPV group p < 0.05
dFisher exact test of comparison with one HR HPV group p < 0.05
eThere were 6 women in total missing tobacco use data
fThere were 5 women in total missing CD4+ lymphocyte nadir data
gThere were a total of 37 women with missing CD4+ lymphocyte data at the time of HPV exam
hThere were 63 women with missing HIV RNA data at the time of HPV exam
Abbreviations used
IQR: interquartile range
cART: combination antiretroviral therapy
ASC-US: atypical squamous cells of unknown significance
AGC: atypical glandular cells
LSIL: low-grade squamous intraepithelial lesion
HSIL: high-grade squamous intraepithelial lesion
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with multiple high-risk types, in particular, were highly
prevalent and associated with abnormal cervical cy-
tology. While HPV 16 infection was common, HPV 58
was the most common HPV type detected overall. Our
study highlighted the role of infection by more than one
high-risk type. Individual pairing frequencies of high-
risk HPV types were relatively low overall; however, the
presence of multiple high-risk HPV types was strongly
associated with abnormal cytology outcomes, even when
adjusting for detection of individual high-risk HPV
types.
In this cohort, infection by high-risk HPV types was
common, occurring in more than half of all women. In-
fection with high-risk HPV types was associated with
younger age and lower CD4+ lymphocyte counts. These
findings are consistent with previous studies of this co-
hort and other studies of HIV-infected women in Brazil
[15, 30–33]. Differing from other studies, tobacco use
Fig. 2 Prevalence of high-risk HPV types and presence of more than one high-risk HPV types by cytology. Abbreviations used: HR: high-risk;
ASC-US: atypical squamous cells of unknown significance, includes atypical glandular cells (n = 1); LSIL: low-grade squamous intraepithelial lesion;
HSIL: high-grade squamous intraepithelial lesion
Fig. 3 Relative frequencies of high-risk HPV pairings in women with abnormal cytology. Includes results from 166 women with abnormal cervical
cytology. Circle size reflects relative frequency of occurrence such that smaller circles reflect less frequent observations. The most frequently
observed pairings are labeled (HPV 31 and HPV 58, n= 10 occurrences; HPV 56 and HPV 58, n = 9 occurrences; HPV 56 and HPV 16, n = 8 occurrences).
Pair = None refers to HPV type frequency alone, without another high risk HPV type
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was not associated with high-risk HPV infection or ab-
normal cervical cytology [32, 34]. Previous work examin-
ing risk of high-grade cervical intra-epithelial neoplasia
by histopathology among women at our clinic demon-
strated an association with tobacco use [35]. The lack of
association observed in this analysis may be a result of
differing outcome measures.
Additionally, infection with more than one high-risk
HPV type was highly prevalent. Women with infections
by more than one high-risk type were notably younger
and had lower CD4 lymphocyte counts compared to
women with high-risk HPV monoinfection. Increased
risk of infection by multiple high-risk HPV types has
been associated in HIV-infection and younger age [36–
39]. We also observed higher frequency of known HIV-
infected sexual partners among women with multiple
high-risk HPV infection compared to those with only
one high-risk HPV detected. While the HIV infection
status of the partner may have affected sexual practices
(though no difference in condom use was reported be-
tween the groups), studies of HIV serodiscordant cou-
ples have shown HIV infection increases the risk of
acquiring HPV infection from uninfected partners in
both women and men [40]. The HIV infection status of
sexual partners thus may be an important risk factor for
HPV infection among HIV-infected women.
In our study, presence of more than one high-risk type
was consistently and independently associated with risk
of abnormal cytology, after adjusting for presence of
individual high-risk types (including HPV 16), age, and
CD4+ lymphocyte count. Infection by more than one
high-risk HPV type has been associated with increasing
risk of cervical intraepithelial neoplasia [38, 41]. A re-
cent study of >59,000 cervical cytology specimens and
HPV genotypes from New Mexico demonstrated that,
with the exception of HPV 16, HPV infection by more
than one high-risk type conferred additional risk of HSIL
compared to monoinfection for each high-risk type ex-
amined. However, risk was not further increased when
more than two high-risk types were detected, suggesting
that risk of high-grade cervical outcomes is not synergis-
tically increased with multiple infections [41]. While
clustering of high-risk HPV types is common, as ob-
served in our study, patterns of specific pairings tend to
be unpredictable. Studies that have statistically examined
clustering patterns of high-risk HPV types have generally
concluded that specific high risk HPV pairings occur at
random [42–44]. Nonetheless, the limited sample size of
most studies precludes statistical inference regarding
patterns of clustering and their impact on the natural
history of cervical cancer. This highlights the importance
of international collaborative studies and meta-analysis
in HIV and HPV research [45].
In this study, high-risk HPV 58 was the most common
HPV type detected in all women, including those with
multiple high-risk types detected and those associated
with abnormal cytology. Worldwide, HPV 16 is the most
frequently detected high-risk type, including in HIV-
Table 2 Unadjusted and adjusted prevalence ratios for abnormal cytology of high-risk HPV types
Unadjusted Prevalence Ratio (PR) Adjusted Prevalence Ratio (aPR)a,b
High risk HPV type HPV type PR [95 % CI] P value HPV type aPR [95 % CI] P value More than one high risk HPV aPR [95 % CI] P value
16 1.48 [1.08–2.01] 0.013 1.14 [0.83–1.54] 0.418 1.94 [1.50–2.52] <0.001c
18 1.19 [0.81–1.74] 0.369 0.83 [0.57–1.20] 0.321 2.04 [1.57–2.66] <0.001c
31 1.53 [1.09–2.13] 0.013 0.97 [0.70–1.37] 0.882 1.98 [1.51–2.59] <0.001c
33 2.13 [1.51–3.02] <0.001 1.47 [1.10–1.97] 0.009 1.89 [1.45–2.46] <0.001c
35 1.89 [1.38–2.59] <0.001 1.20 [0.88–1.64] 0.246 1.88 [1.43–2.48] <0.001c
39 2.03 [1.43–2.88] <0.001 1.09 [0.74–1.61] 0.665 1.95 [1.49–2.53] <0.001c
45 0.80 [0.44–1.50] 0.507 0.58 [0.32–1.06] 0.079 2.07 [1.60–2.68] <0.001c
51 1.35 [0.93–1.97] 0.116 1.00 [0.70–1.43] 0.993 1.97 [1.52–2.56] <0.001c
52 2.05 [1.50–2.81] <0.001 1.35 [1.00–1.84] 0.051 1.89 [1.45–2.46] <0.001c
56 1.74 [1.27–2.38] 0.001 1.06 [0.76–1.47] 0.726 1.94 [1.48–2.55] <0.001c
58 1.29 [0.97–1.72] 0.084 0.90 [0.68–1.21] 0.488 2.04 [1.56–2.68] <0.001c
59 1.34 [0.95–1.89] 0.097 1.00 [0.72–1.38] 0.976 1.97 [1.51–2.57] <0.001c
68 1.53 [1.09–2.16] 0.015 1.04 [0.74–1.46] 0.834 1.96 [1.50–2.56] <0.001c
aDue to missing CD4+ lymphocyte values in 37 women, 525 women were included in multivariate models
bAll adjusted models included individual high-risk HPV type, age, CD4+ lymphocyte count at HPV test, and presence of more than one high risk HPV types. CD4+
lymphocyte count and presence of more than one high-risk HPV types remained statistically significant. Age was not statistically significant in multivariate models




aPR: adjusted prevalence ratio
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infected women [13]. However, the prevalence of high-
risk types other than 16 and 18 is higher in HIV-infected
women compared to uninfected women [13, 14]. HPV
58 has been observed at high rates in multiple studies of
cervical infection in women in Brazil and has been ob-
served at rates above those of HPV 16 in cohorts of
HIV-infected women in Botswana and Zambia [32, 46–
49]. Globally, HPV 58 is the third most prevalent HPV
type detected in cases of cervical cancer [50]. While
HPV 58 was the most frequent high-risk HPV type ob-
served in women with abnormal cytology, further study
is needed in its association with histological measures of
neoplasia, particularly in HIV-infected women. In a lon-
gitudinal study of HIV-uninfected women, HPV 58 was
not as strongly associated with cervical intraepithelial
neoplasia as HPV 16 or 31 [51]. However, the pathogen-
icity of HPV 58 in HIV-infected women has not been
described.
Understanding of epidemiology of specific HPV types,
particularly in high-risk populations like HIV-infected
women, is of critical importance for HPV vaccine devel-
opment and implementation. While studies have sug-
gested cost-effectiveness, general access to the HPV
vaccines is not currently available in Brazil [25]. Import-
antly, second-generation HPV vaccines will include
coverage for a greater number of high-risk HPV types,
including 6,11,16,18, 31, 33, 45, 52, and 58, which could
be particularly important in our population where HPV
58 is highly prevalent. Mathematical models of second-
generation HPV vaccines have predicted even greater ab-
solute risk reduction of cervical cancer compared to
current vaccines. However, models have suggested that
these effects may be blunted by infection by more than
one high-risk type [52]. This study highlights the need
for HPV vaccines that cover for a diversity of high-risk
HPV types and also the need for further information
about their effectiveness in settings of multiple infection.
Our study has important strengths and limitations.
First, this study was designed as a cross-sectional analysis,
which limits our ability to draw conclusions regarding
causality. Additionally, without longitudinal genotype data
available, we did not examine HPV infection clearance or
long-term cytological and histological outcomes in this
analysis. An important strength of our study is the large
cohort of women included for which detailed health and
behavioral information was available through question-
naires. This study reflects the largest epidemiologic
study of HPV genotypes in HIV-infected women in
Latin America. Nonetheless, women who chose to partici-
pate in the cohort may differ with those who declined and,
given the single-center catchment, results from our study
may not be generalizable to other settings. It is notable to
highlight that all women who entered the cohort during
the period of 2005-2013 underwent HPV genotype testing,
thus minimizing the risk of selection bias of those tested.
We used any abnormal cytology results as a composite
outcome of interest rather than LSIL or HSIL. By including
ASC-US outcomes, which are not as strongly associated
with cervical intraepithelial neoplasia, we may have dimin-
ished the ability to detect risk conferred by specific high-
risk HPV types and may have underestimated the effects of
infection by more than one high-risk HPV.
Finally, we included in our analyses those high-risk
types most strongly considered oncogenic. Recently, a
number of HPV types previously considered low-risk
have been recognized to have some oncogenic potential,
namely HPV 26, 53, 66, 67, 69, 70, 73, and 82 [28, 29,
53]. Detection of these viruses would not have occurred
using hybrid capture alone and our study expands the
available data about their epidemiology. HPV 53 was the
second most common HPV type detected overall and
was associated with abnormal cytology in unadjusted
analyses. However, only one woman with monoinfection
by HPV 53 had abnormal cytology (ASC-US) and the as-
sociation of HPV 53 with abnormal cytology was mark-
edly attenuated after adjusting for presence of infection
by more than one high-risk type. Further study into the
persistence, clearance, and long-term outcomes associated
with these possibly oncogenic HPV types is needed.
Conclusions
In conclusion, in a large study of HPV epidemiology in a
cohort of HIV-infected women in Brazil, we found that
infection by high-risk HPV types and infection by more
than one high-risk type were highly prevalent. Infection
by more than one high-risk type was strongly associated
with abnormal cytology, even after adjusting for age,
CD4+ lymphocyte count, and specific high-risk HPV
types. HPV type 58 was the most common HPV type de-
tected overall and among abnormal cytological outcomes.
Further studies on its risk for cervical intraepithelial neo-
plasia and longitudinal outcomes are needed. The diversity
and frequency of infections by more than one high-risk
HPV may have important implications on the effectiveness
of second-generation HPV vaccines. However, the preva-
lence of high-risk HPV infections in this high-risk popula-
tion underscores the importance of all methods of cervical
cancer prevention, including regular screening and vaccine
availability.
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